{"nctId":"NCT02770625","briefTitle":"Phase III Study of ISU302 in Patients With Type 1 Gaucher Disease","startDateStruct":{"date":"2011-09"},"conditions":["Gaucher Disease, Type 1"],"count":8,"armGroups":[{"label":"ISU302","type":"EXPERIMENTAL","interventionNames":["Drug: ISU302"]}],"interventions":[{"name":"ISU302","otherNames":["Imiglucerase"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of Type 1 GD.\n* Documented glucocerebrosidase deficiency.\n* GD-related anemia, defined as hemoglobin levels of at least 1 g/dL below the lower limit of normal for age and gender and one or more of the following 3 criteria:\n\n  * At least moderate splenomegaly (2 to 3 cm below the left costal margin) by palpation,\n  * GD-related thrombocytopenia, defined as a platelet count \\<90 x 109 platelets/L,\n  * GD-related readily palpable enlarged liver.\n* Not received treatment for GD (investigational products, miglustat, velaglucerase alfa, or imiglucerase) within 12 months prior to study entry.\n* Ability to comprehend and willing to sign the ICF.\n* Legal guardian (and patient if age appropriate) understood the nature of the procedure, was willing to comply with associated follow-up evaluations, and provided written informed consent and assent prior to the procedure.\n* Female patients of childbearing potential must had agreed to use a medically acceptable method of contraception at all the times during the study. Male patients must have used a medically acceptable method of birth control throughout their participation in the study and were required to report the pregnancy of a partner.\n\nExclusion Criteria:\n\n* Type 2 or 3 GD.\n* Splenectomy.\n* Antibody positive to ISU302 or imiglucerase during screening or the patient had experienced an anaphylactic reaction to ISU302 or imiglucerase. - Treatment with any non-GD-related investigational drug or medical device within 30 days prior to study entry; such use during the study was also not permitted.\n* Currently receiving red blood cell (RBC) growth factor (eg, erythropoietin) chronic systemic corticosteroids or received such treatment within the last 6 months.\n* Positive for human immunodeficiency virus (HIV) and hepatitis B or C.\n* Exacerbated anemia at screening (due to iron, folic acid, or vitamin B12 deficiency or infectious/immune-mediated cause).\n* Significant comorbidity(ies) that could affect study data or confounded the study results (eg, malignancies, primary biliary cirrhosis, autoimmune liver disease).\n* Pregnant or lactating female patients and those not willing to use highly effective barrier or medical method of contraception.","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Difference in Hemoglobin Concentration [g/dL]","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.49","spread":"0.857"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.44","spread":"0.870"}]}]}]},{"type":"SECONDARY","title":"Platelet Counts [10^3 Platelets/uL]","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"132.6","spread":"72.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"180.3","spread":"47.10"}]}]}]},{"type":"SECONDARY","title":"Spleen Volume","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.047","spread":"18.9140"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.207","spread":"9.4730"}]}]}]},{"type":"SECONDARY","title":"Liver Volume","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.530","spread":"0.6078"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.537","spread":"0.5059"}]}]}]},{"type":"SECONDARY","title":"Angiotensin-converting Enzyme Level","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"195.71","spread":"108.952"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"159.31","spread":"58.253"}]}]}]},{"type":"SECONDARY","title":"Chitotriosidase Level (Nmol/mL/hr)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11093.67","spread":"10354.369"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3409.63","spread":"3103.006"}]}]}]},{"type":"SECONDARY","title":"Chemokine Ligand (CCL-18) Level [ng/mL]","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"927.05","spread":"595.4552"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"577.331","spread":"310.0457"}]}]}]},{"type":"SECONDARY","title":"Acid Phosphatase (ACP) Level (U/L)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.44","spread":"7.517"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.44","spread":"4.313"}]}]}]},{"type":"SECONDARY","title":"Skeletal Status Improvement","description":"The number of participant who have the skeletal status diagnosed as Osteosclerosis","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Bone Mineral Density","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.954","spread":"1.5967"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.104","spread":"2.4558"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Assessment of AEs, Vital Signs, Physical Examination, and Electrocardiogram (ECG)","description":null,"paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":8},"commonTop":[]}}}